WINTON GROUP Ltd Acquires Shares of 14,000 Sanofi $SNY

WINTON GROUP Ltd acquired a new stake in Sanofi (NASDAQ:SNY) during the fourth quarter, HoldingsChannel reports. The firm acquired 14,000 shares of the company’s stock, valued at approximately $678,000.

A number of other institutional investors also recently bought and sold shares of the business. Raymond James Financial Inc. increased its stake in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the period. Mondrian Investment Partners LTD increased its stake in Sanofi by 23.5% in the fourth quarter. Mondrian Investment Partners LTD now owns 4,495,348 shares of the company’s stock valued at $217,845,000 after purchasing an additional 856,742 shares during the period. Natixis Advisors LLC increased its stake in Sanofi by 3.9% in the fourth quarter. Natixis Advisors LLC now owns 3,234,911 shares of the company’s stock valued at $156,764,000 after purchasing an additional 121,530 shares during the period. American Century Companies Inc. increased its stake in Sanofi by 19.4% in the third quarter. American Century Companies Inc. now owns 2,338,969 shares of the company’s stock valued at $110,399,000 after purchasing an additional 379,784 shares during the period. Finally, Northern Trust Corp increased its stake in Sanofi by 1.9% in the third quarter. Northern Trust Corp now owns 2,164,741 shares of the company’s stock valued at $102,176,000 after purchasing an additional 41,250 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SNY. Morgan Stanley set a $52.00 price objective on shares of Sanofi in a research note on Friday, May 1st. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $51.00.

Sanofi Stock Down 2.6%

SNY stock opened at $43.57 on Thursday. The company has a market cap of $105.63 billion, a P/E ratio of 12.17, a P/E/G ratio of 1.10 and a beta of 0.34. Sanofi has a 52 week low of $42.28 and a 52 week high of $52.68. The company’s 50-day moving average price is $45.29 and its 200 day moving average price is $46.60. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a dividend of $2.4225 per share. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s payout ratio is presently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.